title: Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion.
abstract: Human anti-(murine Ig) antibody (HAMA) responses were monitored in 32 patients with unresectable hepatocellular carcinoma (HCC) undergoing radioimmunotherapy using 131I-labeled anti-HCC monoclonal antibody (Hepama-1 mAb) intrahepatic arterial infusion. Dosages of Hepama-1 mAb ranged from 5 mg to 20 mg and the mAb was radiolabeled with 0.74-4.00 GBq (20-108 mCi) 131I (4-6 mCi/mg). T lymphocyte subsets were examined before and after radioimmunotherapy in 24 patients. In this series, 34.4% (11/32) of patients developed HAMA within 2-4 weeks after the infusion. All patients with a negative HAMA response (n = 14), had CD4+ T lymphocyte subsets (T helper/inducer) much lower than those of the HAMA-positive (n = 10) patients and the control group (n = 40) (P < 0.01) prior to infusion. The sequential resection and survival rates in the HAMA-negative group were also lower than that of the HAMA-positive group. Thus, the determination of T lymphocyte subsets might help to predict the HAMA response in HCC patients during radioimmunotherapy.
authors.affiliation: Liver Cancer Institute, Shanghai Medical University, P.R. China.
authors.forename: Z C
authors.initials: ZC
authors.lastname: Zeng
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Tang
authors.forename: K D
authors.initials: KD
authors.lastname: Liu
authors.forename: J Z
authors.initials: JZ
authors.lastname: Lu
authors.forename: X J
authors.initials: XJ
authors.lastname: Cai
authors.forename: H
authors.initials: H
authors.lastname: Xie
mesh_terms: D000328:Adult; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D016516:CD4-CD8 Ratio; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D016499:Radioimmunotherapy; D015996:Survival Rate
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes